Skip to main content
Fig. 2 | Journal for ImmunoTherapy of Cancer

Fig. 2

From: Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide

Fig. 2

Anti-PD-1 treatment is ineffective alone, but increases efficacy of DPX vaccination and mCPA. Mice were implanted with C3 tumors and treated with isotype control antibody (n = 10) or anti-PD-1 (n = 10) on study days 15, 18, 21, 29, 32, 35; average tumor volume a and survival b. Mice bearing C3 tumors were treated with mCPA for 1 week starting 8 and 22 days after implantation and vaccinated with DPX-R9F on days 15 and 29 (n = 30), anti-PD-1 was provided on study days 15, 18, 21, 29, 32, 35 (n = 30); average tumor volume c and survival d. Statistics of tumor volume by linear regression and survival by Mantel-Cox, *p < 0.05

Back to article page